"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
Calcium Chloride Injection 10%
Inadvertent systemic overloading with calcium ion can produce an acute hypercalcemic syndrome. The syndrome is characterized by weakness, lethargy, intractable nausea and vomiting, coma, and sudden death, and a markedly elevated plasma calcium level. It is suggested that details of treatment of this problem be obtained by reference to Harrison's Principles of Internal Medicine Sixth Edition, pg. 475, column 2, “Acute Hypercalcemic Syndrome”.
Store at controlled room temperature 15°-30°C (59°-86°F) (See USP).
In cardiac resuscitation, the use of calcium chloride (calcium chloride) is contraindicated in the presence of ventricular fibrillation.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/30/2008
Additional Calcium Chloride Injection 10% Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.